Tag Archives: drug

Gilead’s Veklury becomes first FDA-approved drug for treating COVID-19

Dive Brief: The Food and Drug Administration has granted a full approval to Gilead’s COVID-19 drug Veklury, making it the first medicine to win a standard clearance from the agency to treat the disease caused by the new coronavirus. The FDA authorized Veklury for emergency use in May, a declaration that’s only valid during a… Read More »

Drug company influence on journalism

Many times through the years, HealthNewsReview.org has criticized the National Press Foundation in Washington, DC, for accepting drug company funding for journalism training.  (See articles from June 2009, July 2009, August 2010, September 2010, October 2010, March 2014, March 2015, December 2015, November 2019. I may have missed a few, but you get the picture.) They’re doing it… Read More »

It has come to this: ignore vaccines-in-animals drug industry PR & news

A long-haired male golden hamster (via Wikipedia & Creative Commons) Earlier this week, a powerful opinion piece, “It Has Come To This:  Ignore the CDC,”  co-authored by former National Institutes of Health director Harold Varmus,  was published in the New York Times. That’s on the science side. On the PR and journalism side, it has… Read More »

Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week

After the late Rep. Elijah Cummings launched a drug pricing probe of some of the industry’s largest players last January, six pharmaceutical execs are set to head to Washington next week for hearings at the House Committee on Oversight and Reform.  Current and former executives from Celgene, Bristol Myers Squibb, Teva, Amgen, Mallinckrodt and Novartis will testify next Wednesday… Read More »

UnitedHealthcare spurns Gilead’s newer PrEP drug Descovy as Truvada generic looms: report

UnitedHealthcare has a history of limiting HIV drug costs, including offering cash incentives to patients who opt for low-priced regimens. Now, in a potentially major blow to HIV giant Gilead Sciences, the insurer has set its eyes on one of the California drugmaker’s new therapies. Gilead’s new HIV PrEP option, Descovy, will no longer be covered… Read More »